Transaction DateRecipientSharesTypePriceValue
24th September 2020David N Gill8,000Open or private purchase$2.13$17,040.00
18th September 2020Associates, L.L.C. Cdk6,000Open or private purchase$2.20$13,200.00
17th September 2020Associates, L.L.C. Cdk1,473,377Open or private purchase$2.25$3,315,098.25
15th September 2020Matthew Pauls227,272Grant/award etc.$0.00
3rd September 2020David N Gill23,104Payment by withholding$3.61$83,405.44
13th August 2020A Brian Davis7,900Open or private purchase$6.24$49,296.00
6th July 2020Jeffrey W Sherman9,100Open or private sale$57.50$523,250.00
2nd July 2020John Johnson315,000Grant/award etc.$0.00
2nd July 2020John Johnson13,194Sale back to the issuer$18.00$237,492.00
2nd July 2020John Johnson7,281Sale back to the issuer$18.00$131,058.00
Strongbridge Biopharma Plc
Strongbridge Biopharma Plc logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.

Strongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company. The company focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide.

Ticker: SBBP
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1634432
Employees: 71
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $60 M (0%)
Inventory, Net: $1 M (-34%)
Assets, Current: $66 M (-20%)
Property, Plant and Equipment, Net: $248 Th (-14%)
Other Assets, Noncurrent: $812 Th (25%)
Assets: $98 M (-17%)
Liabilities, Current: $19 M (-19%)
Other Liabilities, Noncurrent: $972 Th (-10%)
Liabilities: $50 M (9%)
Common Stock, Value, Issued: $544 Th (0%)
Additional Paid in Capital, Common Stock: $338 M (1%)
Retained Earnings (Accumulated Deficit): $290 M (11%)
Liabilities and Equity: $98 M (-17%)
Revenue: $8 M (-46%)
Research and Development: $6 M (-55%)
Operating Income/Loss: $10 M (-58%)
Other Income, net: $8 M (11%)
EPS (basic): $0.32 (-41%)
EPS (diluted): $0.32 (-41%)